Warning letter
CP Pharmaceuticals, Ltd. [ARCHIVED]: warning letter of Oct 29, 2010
FDA warning letter 141790 · Center for Drug Evaluation and Research
Key facts
| Reference number | 141790 |
|---|---|
| Company | CP Pharmaceuticals, Ltd. [ARCHIVED] |
| Subject | CGMP for Finished Pharmaceuticals/Adulterated |
| Issue date | Oct 29, 2010 |
| Posted date | Oct 29, 2010 |
| Issuing office | Center for Drug Evaluation and Research |
| Product type | Drugs |
| CFR sections cited | 211.192, 211.42(c), 211.160(b) |
| Inspection city | Wrexham |
| Inspection start date | Jul 22, 2010 |
| Letter on fda.gov | web.archive.org |
At a glance
- 1–9 CFR sections cited
- OAI Linked inspection classification
- Yes Form FDA 483 issued
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA warning letters
FDA warning letters notify a firm of significant regulatory violations found during an inspection or review and request prompt corrective action.
Source: U.S. Food and Drug Administration (FDA), Warning Letters · Source date: